| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12185-011-0821-Z |
| P8608 | Fatcat ID | release_t3apkqiqc5hibcqtpqenstolku |
| P698 | PubMed publication ID | 21451957 |
| P5875 | ResearchGate publication ID | 50937349 |
| P2093 | author name string | Hui Liu | |
| Jian Huang | |||
| Xin Sun | |||
| Jie Jin | |||
| Min Yang | |||
| Ting Ding | |||
| P2860 | cites work | Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin | Q28476078 |
| Activators and target genes of Rel/NF-kappaB transcription factors | Q29547882 | ||
| A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes | Q34203659 | ||
| NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs) | Q34560200 | ||
| Proteasome inhibitors in the treatment of multiple myeloma | Q34611676 | ||
| The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms | Q35009549 | ||
| Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks | Q35743146 | ||
| The role of proteasome inhibitors in solid tumors | Q35821596 | ||
| Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs | Q36085634 | ||
| Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes. | Q36194610 | ||
| The proteasome as a potential target for novel anticancer drugs and chemosensitizers | Q36695969 | ||
| Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome | Q36988558 | ||
| Proteasome inhibitors: a therapeutic strategy for haematological malignancy | Q37175286 | ||
| Novel therapies for relapsed myeloma | Q37653290 | ||
| Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. | Q37676478 | ||
| Proteasome system of protein degradation and processing | Q37704419 | ||
| The development and pharmacology of proteasome inhibitors for the management and treatment of cancer | Q37709559 | ||
| An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis | Q38290395 | ||
| Bcl-2 changes conformation to inhibit Bax oligomerization | Q40287064 | ||
| NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome | Q40362293 | ||
| The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis | Q40425646 | ||
| Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer | Q40531487 | ||
| In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1. | Q41117851 | ||
| Death receptor-induced signaling pathways are differentially regulated by gamma interferon upstream of caspase 8 processing | Q42141887 | ||
| Akt associates with nuclear factor kappaB and plays an important role in chemoresistance of gastric cancer cells | Q43049489 | ||
| Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition | Q44057694 | ||
| The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications | Q44211035 | ||
| Mechanism of cytosine arabinoside-mediated apoptosis: role of Rel A (p65) dephosphorylation | Q44508743 | ||
| Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line | Q44563849 | ||
| Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients | Q46845164 | ||
| World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. | Q53561569 | ||
| Myelodysplastic Syndromes | Q56639444 | ||
| Nuclear factor k B is activated in myelodysplastic bone marrow cells | Q74753350 | ||
| Myelodysplastic syndromes | Q82442488 | ||
| Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90 | Q83115248 | ||
| Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma | Q84550995 | ||
| P433 | issue | 4 | |
| P921 | main subject | myelodysplastic syndrome | Q954625 |
| P304 | page(s) | 482-493 | |
| P577 | publication date | 2011-03-31 | |
| P1433 | published in | International Journal of Hematology | Q6051416 |
| P1476 | title | Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells | |
| P478 | volume | 93 |
| Q39145987 | Functional exploration of colorectal cancer genomes using Drosophila |
| Q37031282 | Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase |
| Q64240643 | Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3 |
| Q35114769 | Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors |
| Q38821561 | Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis |
Search more.